Cisplatin therapy in childhood: renal follow up 3 years or more after treatment. Swiss Pediatric Oncology Group

Details

Serval ID
serval:BIB_E54B20FE2CFB
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Cisplatin therapy in childhood: renal follow up 3 years or more after treatment. Swiss Pediatric Oncology Group
Journal
Nephrology, Dialysis, Transplantation
Author(s)
von der Weid  N. X., Erni  B. M., Mamie  C., Wagner  H. P., Bianchetti  M. G.
ISSN
0931-0509 (Print)
Publication state
Published
Issued date
06/1999
Volume
14
Number
6
Pages
1441-4
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Jun
Abstract
BACKGROUND: In childhood, cisplatin is an essential component of solid tumour therapy such as in neuroblastomas, germ cell tumours, bone tumours, liver tumours and brain tumours. The potential nephotoxicity of cisplatin is widely recognized, but little information is available on permanent sequelae. METHODS: Of the 500 children included in the Swiss Pediatric Oncology Group Late Effect Study, a group of 46 patients (27 males and 19 females) aged 5.7-28 years (median 14 years) surviving the above-mentioned solid tumours entered the present study. The patients were disease-free and off antineoplastic medication for at least 3 years. No recent gastrointestinal or urinary disturbances had occurred, and diets as well as appetites were normal. RESULTS: Blood pressure and plasma or urinary calcium and phosphate were similar in 17 patients treated with cisplatin (dose 142-717, median 400 mg/m2), in 19 patients without cisplatin and in 20 control subjects. A tendency (P<0.02) towards increased plasma creatinine (79 (69-89) micromol/l; median and interquartile range) and low plasma magnesium (0.80 (0.78-0.85) mmol/l) was noted in patients treated with cisplatin as compared with those without cisplatin (68 (58-80) micromol/l; 0.84 (0.79-0.90) mmol/l) and controls (71 (64 80) micromol/l; 0.83 (0.80-0.90) mmol/l). No correlation was noted between the dosage of cisplatin and circulating magnesium or creatinine. CONCLUSIONS: The study demonstrates that the permanent renal disturbances ((i) decreased renal function and (ii) hypomagnesaemia) noted after treatment with cisplatin during infancy or childhood are mild. Furthermore, the study does not demonstrate renal sequelae in patients with the same malignancies who had been treated without cisplatin.
Keywords
Adolescent Adult Antineoplastic Agents/*adverse effects Child Cisplatin/*adverse effects Female Follow-Up Studies Glomerular Filtration Rate/drug effects Humans Kidney/*drug effects Male Time Factors
Pubmed
Web of science
Open Access
Yes
Create date
25/01/2008 10:35
Last modification date
20/08/2019 16:08
Usage data